Pathophysiology of Interstitial Cystitis/Bladder Pain Syndrome

Introduction to IC/BPS

Interstitial cystitis/bladder pain syndrome (IC/BPS) is a bladder pain disorder characterized by urothelial dysfunction, chronic inflammation, and neural upregulation, often existing as part of a broader systemic hypersensitivity syndrome rather than an isolated bladder pathology 1, 2

The American Urological Association suggests that IC/BPS may represent either a primary bladder disorder or bladder symptoms secondary to systemic dysregulation 1, 2, 3
The most current understanding conceptualizes IC/BPS as a member of a family of hypersensitivity disorders affecting multiple somatic and visceral organs with overlapping pathophysiology 1, 2, 4

IC/BPS commonly coexists with fibromyalgia, irritable bowel syndrome, chronic fatigue syndrome, Sjögren's syndrome, chronic headaches, and vulvodynia, suggesting systemic dysregulation rather than isolated bladder disease 1, 2, 3
Some patients exhibit IC/BPS as part of a continuum with overactive bladder syndrome, sharing pathophysiologic mechanisms 1, 2, 4
Mental health disorders including depression and anxiety frequently co-occur, with evidence suggesting a common biological mechanism rather than purely reactive symptoms 1, 2, 3

The Society of Urologic Nurses and Associates recommends urothelial barrier repair with GAG layer replacement agents like hyaluronic acid or pentosan polysulfate as a key pathophysiologic target for treatment 5
The European Association of Urology suggests inflammation reduction through various anti-inflammatory approaches as a necessary treatment component 5
Neural modulation to address peripheral and central sensitization is a crucial aspect of IC/BPS treatment, according to the International Continence Society 5
Pain pathway interruption throughout the treatment course is essential, as stated by the American College of Physicians 5